ASLMS 2026: Lumenis Reports New Laser Findings in Scalp Treatment, Rhinophyma, Photodamaged Skin

Lumenis Be Ltd. presented new clinical data on several aesthetic devices at the 45th Annual American Society for Laser Medicine and Surgery Conference, held May 7-9, 2026, in Savannah, Georgia, according to a company announcement.

The presentations included data on FoLix, a 1565-nm nonablative fractional laser cleared by the FDA for improving the appearance of scalp hair in adult male and female patients with Fitzpatrick skin types I to IV seeking treatment for hair loss. In a randomized prospective study led by Jennifer Krejci, MD, investigators reported statistically significant improvements in terminal hair count, total hair count, and follicular density among patients with androgenetic alopecia, with up to 82% showing measurable benefit. A second study led by Neil Sadick, MD, evaluated mechanistic findings in human subjects and reported stimulation of angiogenesis and dermal remodeling.

Additional data focused on the ULTRApulse Alpha CO₂ laser for rhinophyma. In a 15-patient study of fully ablative CO₂ laser resurfacing in patients receiving low-dose oral isotretinoin, investigators reported improved Rhinophyma Severity Index scores, 100% patient satisfaction, no delayed healing or abnormal scarring, and universal willingness to recommend the treatment.

Lumenis also presented e-poster data on Stellar M22 XPL Repeat Mode for large-area treatment of photodamaged skin. The single-center prospective study evaluated a combined glide-and-stamp technique using high-frequency repeat mode up to 4 Hz. Investigators reported improved skin appearance and lesion clearance without conventional striping or treatment-related adverse events.

"At Lumenis, clinical evidence is the engine that drives our innovation forward,” CEO Tzipi Ozer-Armon said in a press release. “The data presented at ASLMS highlights our continued commitment to anticipating what's next in aesthetics and transforming rigorous science into advanced, clinically validated solutions. As patient expectations continue to evolve, our focus remains on arming clinicians with the most cutting‑edge tools available, empowering them to deliver superior, consistent outcomes and confidently shape the future of patient care."

Source

Lumenis Be. Ltd. Lumenis Aesthetics Showcases New Clinical Data Across Skin and Hair Loss Indications at 45th Annual American Society for Laser Medicine and Surgery Conference. PR Newswire. Published May 9, 2026. Accessed May 11, 2026.https://www.prnewswire.com/news-releases/lumenis-aesthetics-showcases-new-clinical-data-across-skin-and-hair-loss-indications-at-45th-annual-american-society-for-laser-medicine-and-surgery-conference-302767494.html